{"name":"Abbott Laboratories","slug":"abbott","ticker":"ABT","exchange":"NYSE","domain":"abbott.com","description":"Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.","hq":"Abbott Park, IL","founded":0,"employees":"115000","ceo":"Robert B. Ford","sector":"Diversified Healthcare / Medical Devices","stockPrice":103.32,"stockChange":1.49,"stockChangePercent":1.46,"marketCap":"$179.5B","metrics":{"revenue":44328000000,"revenueGrowth":4.4,"grossMargin":56.7,"rdSpend":2942000000,"netIncome":6524000000,"cash":8938999808,"dividendYield":2.46,"peRatio":27.8,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"1972-01-01","label":"Calcium Gluceptate first approved","drug":"Calcium Gluceptate","drugSlug":"calcium-glucoheptonate","type":"approval","sentiment":"positive"},{"date":"1981-01-01","label":"Golytely first approved","drug":"Golytely","drugSlug":"sodium-bicarbonate","type":"approval","sentiment":"positive"},{"date":"1990-01-01","label":"Prosom first approved","drug":"Prosom","drugSlug":"estazolam","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-06-01","label":"Humira patent cliff ($10.3B at risk)","drug":"Humira","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":20,"colorKey":"oncology","drugs":[{"name":"Golytely","genericName":"Sodium Bicarbonate","slug":"sodium-bicarbonate","indication":"Reduction of risk of upper gastrointestinal bleeding","status":"marketed"},{"name":"Venocur Triplex®","genericName":"Venocur Triplex®","slug":"venocur-triplex","indication":"Other","status":"marketed"},{"name":"paricalcitol capsules","genericName":"paricalcitol capsules","slug":"paricalcitol-capsules","indication":"Secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis","status":"marketed"},{"name":"ABT-614","genericName":"ABT-614","slug":"abt-614","indication":"Other","status":"phase_1"},{"name":"ABT-SLV361","genericName":"ABT-SLV361","slug":"abt-slv361","indication":"Other","status":"phase_1"},{"name":"Calcijex","genericName":"Calcijex","slug":"calcijex","indication":"Other","status":"marketed"},{"name":"Calcium Gluceptate","genericName":"calcium glucoheptonate","slug":"calcium-glucoheptonate","indication":"Cardiac arrest","status":"marketed"},{"name":"Cortiment","genericName":"Cortiment","slug":"cortiment","indication":"Other","status":"phase_1"},{"name":"Creon IR","genericName":"Creon IR","slug":"creon-ir","indication":"Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions","status":"phase_2"},{"name":"Creon N","genericName":"Creon N","slug":"creon-n","indication":"Exocrine pancreatic insufficiency","status":"phase_3"},{"name":"Creon® 10000","genericName":"Creon® 10000","slug":"creon-10000","indication":"Exocrine pancreatic insufficiency due to cystic fibrosis","status":"phase_3"},{"name":"Cytochrome P450 inhibitor","genericName":"Cytochrome P450 inhibitor","slug":"cytochrome-p450-inhibitor","indication":"Other","status":"phase_1"},{"name":"Fat Emulsion 2%","genericName":"Fat Emulsion 2%","slug":"fat-emulsion-2","indication":"Other","status":"phase_1"},{"name":"Hectorol® injection","genericName":"Hectorol® injection","slug":"hectorol-injection","indication":"Other","status":"marketed"},{"name":"Metofane","genericName":"METHOXYFLURANE","slug":"methoxyflurane","indication":"Other","status":"marketed"},{"name":"Mitizax","genericName":"Mitizax","slug":"mitizax","indication":"Other","status":"phase_3"},{"name":"Prosom","genericName":"ESTAZOLAM","slug":"estazolam","indication":"Severe Insomnia","status":"marketed"},{"name":"Sevoflurane Inhalational Induction and Maintenance","genericName":"Sevoflurane Inhalational Induction and Maintenance","slug":"sevoflurane-inhalational-induction-and-maintenance","indication":"Induction and maintenance of general anesthesia in adult and pediatric patients undergoing surgery","status":"marketed"},{"name":"Testosterone (T) Gel 1.62%","genericName":"Testosterone (T) Gel 1.62%","slug":"testosterone-t-gel-1-62","indication":"Testosterone replacement therapy in adult males with hypogonadism","status":"phase_3"},{"name":"paricalcitol capsule","genericName":"paricalcitol capsule","slug":"paricalcitol-capsule","indication":"Secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"metabolic","drugs":[{"name":"Lotrel (amlodipine/benazepril)","genericName":"Lotrel (amlodipine/benazepril)","slug":"lotrel-amlodipine-benazepril","indication":"Hypertension","status":"marketed"},{"name":"Niacin ER/Simvastatin Tablets","genericName":"Niacin ER/Simvastatin Tablets","slug":"niacin-er-simvastatin-tablets","indication":"Hyperlipidemia and mixed dyslipidemia in patients requiring both statin and niacin therapy","status":"phase_3"},{"name":"Pentothal","genericName":"THIOPENTAL","slug":"thiopental","indication":"Benign intracranial hypertension","status":"marketed"},{"name":"Placebo Eprosartan mesylate","genericName":"Placebo Eprosartan mesylate","slug":"placebo-eprosartan-mesylate","indication":"Hypertension","status":"phase_3"},{"name":"aspirin placebo (ASA Pbo)","genericName":"aspirin placebo (ASA Pbo)","slug":"aspirin-placebo-asa-pbo","indication":"Prevention of cardiovascular disease and stroke","status":"phase_3"},{"name":"felodipine/ramipril","genericName":"felodipine/ramipril","slug":"felodipine-ramipril","indication":"Hypertension","status":"phase_3"},{"name":"metoprolol/HCT","genericName":"metoprolol/HCT","slug":"metoprolol-hct","indication":"Hypertension","status":"phase_3"},{"name":"sibutramine hydochloride monohydrate","genericName":"sibutramine hydochloride monohydrate","slug":"sibutramine-hydochloride-monohydrate","indication":"Obesity management (withdrawn from most markets due to cardiovascular safety concerns)","status":"marketed"},{"name":"trandolapril/verapamil","genericName":"trandolapril/verapamil","slug":"trandolapril-verapamil","indication":"Hypertension","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"respiratory","drugs":[{"name":"Double-Blind Adalimumab/Placebo + MTX","genericName":"Double-Blind Adalimumab/Placebo + MTX","slug":"double-blind-adalimumab-placebo-mtx","indication":"Rheumatoid arthritis (in combination with methotrexate)","status":"phase_3"},{"name":"Double-blind adalimumab","genericName":"Double-blind adalimumab","slug":"double-blind-adalimumab","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"OLE BSA Adalimumab +/- MTX","genericName":"OLE BSA Adalimumab +/- MTX","slug":"ole-bsa-adalimumab-mtx","indication":"Rheumatoid arthritis (with or without methotrexate)","status":"phase_3"},{"name":"OLE FD Adalimumab +/- MTX","genericName":"OLE FD Adalimumab +/- MTX","slug":"ole-fd-adalimumab-mtx","indication":"Rheumatoid arthritis (with or without methotrexate)","status":"phase_3"},{"name":"Open-labelAdalimumabRescue","genericName":"Open-labelAdalimumabRescue","slug":"open-labeladalimumabrescue","indication":"Rescue therapy in inflammatory bowel disease (Crohn's disease or ulcerative colitis) with inadequate response to standard therapy","status":"phase_3"},{"name":"adalimumab (D2E7)","genericName":"adalimumab (D2E7)","slug":"adalimumab-d2e7","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"placebo adalimumab, placebo MTX","genericName":"placebo adalimumab, placebo MTX","slug":"placebo-adalimumab-placebo-mtx","indication":"Rheumatoid arthritis","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"clarithromycin immediate-release tablets","genericName":"clarithromycin immediate-release tablets","slug":"clarithromycin-immediate-release-tablets","indication":"Community-acquired pneumonia","status":"phase_3"},{"name":"Ademetionine IV+tablet","genericName":"Ademetionine IV+tablet","slug":"ademetionine-iv-tablet","indication":"Cholestasis and liver disease","status":"phase_3"},{"name":"Lopinavir/ritonavir (Kaletra)","genericName":"Lopinavir/ritonavir (Kaletra)","slug":"lopinavir-ritonavir-kaletra","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"marketed"},{"name":"Racecadotril plus ORS","genericName":"Racecadotril plus ORS","slug":"racecadotril-plus-ors","indication":"Acute diarrhea in children","status":"phase_3"},{"name":"cefdinir (Omnicef)","genericName":"cefdinir (Omnicef)","slug":"cefdinir-omnicef","indication":"Community-acquired pneumonia","status":"marketed"},{"name":"raltegravir (RAL)","genericName":"raltegravir (RAL)","slug":"raltegravir-ral","indication":"HIV-1 infection in treatment-naïve adults and children","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"infectious","drugs":[{"name":"Buffered pantoprazole","genericName":"Buffered pantoprazole","slug":"buffered-pantoprazole","indication":"Gastroesophageal reflux disease (GERD)","status":"marketed"},{"name":"Hydrocodone/Acetaminophen on Extended Release","genericName":"Hydrocodone/Acetaminophen on Extended Release","slug":"hydrocodone-acetaminophen-on-extended-release","indication":"Moderate to severe pain requiring opioid therapy","status":"phase_3"},{"name":"Mebeverine+Simethicone","genericName":"Mebeverine+Simethicone","slug":"mebeverine-simethicone","indication":"Irritable bowel syndrome with abdominal pain, cramping, and bloating","status":"phase_3"},{"name":"hydrocodone / acetaminophen extended release","genericName":"hydrocodone / acetaminophen extended release","slug":"hydrocodone-acetaminophen-extended-release","indication":"Management of moderate to severe pain","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"ABT-335 and atorvastatin calcium","genericName":"ABT-335 and atorvastatin calcium","slug":"abt-335-and-atorvastatin-calcium","indication":"Dyslipidemia with elevated triglycerides and LDL cholesterol","status":"phase_3"},{"name":"ABT-335 and simvastatin","genericName":"ABT-335 and simvastatin","slug":"abt-335-and-simvastatin","indication":"Dyslipidemia with elevated triglycerides and LDL cholesterol","status":"phase_3"},{"name":"SA-001","genericName":"SA-001","slug":"sa-001","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"rare","drugs":[{"name":"Leuprolide acetate - Formulation A","genericName":"Leuprolide acetate - Formulation A","slug":"leuprolide-acetate-formulation-a","indication":"Advanced prostate cancer","status":"phase_3"},{"name":"Leuprolide acetate - Formulation B","genericName":"Leuprolide acetate - Formulation B","slug":"leuprolide-acetate-formulation-b","indication":"Advanced prostate cancer","status":"phase_3"},{"name":"Lupron (leuprolide acetate)","genericName":"Lupron (leuprolide acetate)","slug":"lupron-leuprolide-acetate","indication":"Advanced prostate cancer","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Ademetionine tablet","genericName":"Ademetionine tablet","slug":"ademetionine-tablet","indication":"Cholestasis and intrahepatic cholestasis of pregnancy","status":"phase_3"}]}],"pipeline":[{"name":"Golytely","genericName":"Sodium Bicarbonate","slug":"sodium-bicarbonate","phase":"marketed","mechanism":"Golytely works by neutralizing stomach acid and helping to protect the stomach lining.","indications":["Reduction of risk of upper gastrointestinal bleeding"],"catalyst":""},{"name":"Venocur Triplex®","genericName":"Venocur Triplex®","slug":"venocur-triplex","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"clarithromycin immediate-release tablets","genericName":"clarithromycin immediate-release tablets","slug":"clarithromycin-immediate-release-tablets","phase":"phase_3","mechanism":"Clarithromycin is a macrolide antibiotic that inhibits protein synthesis by binding to the 50S ribosomal subunit.","indications":["Community-acquired pneumonia","Acute bacterial exacerbation of chronic bronchitis","Mild to moderate adult and pediatric patients with acute maxillary sinusitis"],"catalyst":""},{"name":"paricalcitol capsules","genericName":"paricalcitol capsules","slug":"paricalcitol-capsules","phase":"marketed","mechanism":"Paricalcitol is a selective vitamin D receptor agonist that activates the vitamin D receptor to regulate calcium and phosphate metabolism and suppress parathyroid hormone secretion.","indications":["Secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis","Secondary hyperparathyroidism in patients with chronic kidney disease stages 3-4 not on dialysis"],"catalyst":""},{"name":"ABT-335 and atorvastatin calcium","genericName":"ABT-335 and atorvastatin calcium","slug":"abt-335-and-atorvastatin-calcium","phase":"phase_3","mechanism":"ABT-335 is a fibrate that reduces triglycerides and raises HDL cholesterol, combined with atorvastatin calcium which inhibits HMG-CoA reductase to lower LDL cholesterol.","indications":["Dyslipidemia with elevated triglycerides and LDL cholesterol"],"catalyst":""},{"name":"ABT-335 and simvastatin","genericName":"ABT-335 and simvastatin","slug":"abt-335-and-simvastatin","phase":"phase_3","mechanism":"ABT-335 (fenofibrate) combined with simvastatin works by reducing triglycerides and LDL cholesterol through dual lipid-lowering pathways.","indications":["Dyslipidemia with elevated triglycerides and LDL cholesterol"],"catalyst":""},{"name":"ABT-614","genericName":"ABT-614","slug":"abt-614","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABT-SLV361","genericName":"ABT-SLV361","slug":"abt-slv361","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ademetionine IV+tablet","genericName":"Ademetionine IV+tablet","slug":"ademetionine-iv-tablet","phase":"phase_3","mechanism":"Ademetionine is a methyl donor that replenishes cellular methylation capacity and supports hepatic function and neurotransmitter synthesis.","indications":["Cholestasis and liver disease","Hepatic cirrhosis","Drug-induced liver injury"],"catalyst":""},{"name":"Ademetionine tablet","genericName":"Ademetionine tablet","slug":"ademetionine-tablet","phase":"phase_3","mechanism":"Ademetionine is a methyl donor that replenishes cellular S-adenosylmethionine (SAM) levels to support methylation reactions and hepatic function.","indications":["Cholestasis and intrahepatic cholestasis of pregnancy","Hepatic cirrhosis and liver dysfunction","Depression (secondary indication in some markets)"],"catalyst":""},{"name":"Buffered pantoprazole","genericName":"Buffered pantoprazole","slug":"buffered-pantoprazole","phase":"marketed","mechanism":"Buffered pantoprazole inhibits gastric acid secretion by blocking the proton pump (H+/K+-ATPase) in parietal cells of the stomach.","indications":["Gastroesophageal reflux disease (GERD)","Peptic ulcer disease","Zollinger-Ellison syndrome","Prevention of NSAID-induced ulcers"],"catalyst":""},{"name":"Calcijex","genericName":"Calcijex","slug":"calcijex","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Calcium Gluceptate","genericName":"calcium glucoheptonate","slug":"calcium-glucoheptonate","phase":"marketed","mechanism":"","indications":["Cardiac arrest","Disorder of electrolytes","Hyperkalemia","Hypermagnesemia","Hypocalcemia"],"catalyst":""},{"name":"Cortiment","genericName":"Cortiment","slug":"cortiment","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Creon IR","genericName":"Creon IR","slug":"creon-ir","phase":"phase_2","mechanism":"Pancreatic enzyme replacement","indications":["Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions"],"catalyst":""},{"name":"Creon N","genericName":"Creon N","slug":"creon-n","phase":"phase_3","mechanism":"Creon N is a pancreatic enzyme replacement therapy that provides lipase, protease, and amylase to aid digestion of fats, proteins, and carbohydrates in patients with pancreatic insufficiency.","indications":["Exocrine pancreatic insufficiency","Cystic fibrosis","Chronic pancreatitis","Post-pancreatic surgery"],"catalyst":""},{"name":"Creon® 10000","genericName":"Creon® 10000","slug":"creon-10000","phase":"phase_3","mechanism":"Creon 10000 is a pancreatic enzyme replacement therapy that supplies lipase, protease, and amylase to aid digestion of fats, proteins, and carbohydrates in patients with pancreatic insufficiency.","indications":["Exocrine pancreatic insufficiency due to cystic fibrosis","Exocrine pancreatic insufficiency due to chronic pancreatitis","Exocrine pancreatic insufficiency due to pancreatic surgery"],"catalyst":""},{"name":"Cytochrome P450 inhibitor","genericName":"Cytochrome P450 inhibitor","slug":"cytochrome-p450-inhibitor","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Double-Blind Adalimumab/Placebo + MTX","genericName":"Double-Blind Adalimumab/Placebo + MTX","slug":"double-blind-adalimumab-placebo-mtx","phase":"phase_3","mechanism":"Adalimumab is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha signaling to reduce inflammation, combined with methotrexate for enhanced immunosuppressive effect.","indications":["Rheumatoid arthritis (in combination with methotrexate)","Polyarticular juvenile idiopathic arthritis","Ankylosing spondylitis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"Double-blind adalimumab","genericName":"Double-blind adalimumab","slug":"double-blind-adalimumab","phase":"phase_3","mechanism":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Ankylosing spondylitis","Psoriatic arthritis"],"catalyst":""},{"name":"Fat Emulsion 2%","genericName":"Fat Emulsion 2%","slug":"fat-emulsion-2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Hectorol® injection","genericName":"Hectorol® injection","slug":"hectorol-injection","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Hydrocodone/Acetaminophen on Extended Release","genericName":"Hydrocodone/Acetaminophen on Extended Release","slug":"hydrocodone-acetaminophen-on-extended-release","phase":"phase_3","mechanism":"Hydrocodone is an opioid agonist that binds to mu opioid receptors in the central nervous system to reduce pain, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects.","indications":["Moderate to severe pain requiring opioid therapy"],"catalyst":""},{"name":"Leuprolide acetate - Formulation A","genericName":"Leuprolide acetate - Formulation A","slug":"leuprolide-acetate-formulation-a","phase":"phase_3","mechanism":"Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone and estrogen production.","indications":["Advanced prostate cancer","Endometriosis","Uterine fibroids (leiomyomata)","Central precocious puberty"],"catalyst":""},{"name":"Leuprolide acetate - Formulation B","genericName":"Leuprolide acetate - Formulation B","slug":"leuprolide-acetate-formulation-b","phase":"phase_3","mechanism":"Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production.","indications":["Advanced prostate cancer","Endometriosis","Uterine fibroids","Precocious puberty","Breast cancer (hormone-receptor positive)"],"catalyst":""},{"name":"Lopinavir/ritonavir (Kaletra)","genericName":"Lopinavir/ritonavir (Kaletra)","slug":"lopinavir-ritonavir-kaletra","phase":"marketed","mechanism":"Lopinavir and ritonavir are protease inhibitors that block HIV protease, preventing the cleavage of viral polyproteins and stopping HIV replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients","HIV-1 infection in combination antiretroviral therapy"],"catalyst":""},{"name":"Lotrel (amlodipine/benazepril)","genericName":"Lotrel (amlodipine/benazepril)","slug":"lotrel-amlodipine-benazepril","phase":"marketed","mechanism":"Lotrel combines a calcium channel blocker and an ACE inhibitor to lower blood pressure through two complementary pathways: relaxing blood vessel smooth muscle and reducing angiotensin II-mediated vasoconstriction.","indications":["Hypertension","Angina pectoris"],"catalyst":""},{"name":"Lupron (leuprolide acetate)","genericName":"Lupron (leuprolide acetate)","slug":"lupron-leuprolide-acetate","phase":"phase_3","mechanism":"Leuprolide is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone and estrogen production.","indications":["Advanced prostate cancer","Endometriosis","Uterine fibroids (leiomyomata)","Central precocious puberty"],"catalyst":""},{"name":"Mebeverine+Simethicone","genericName":"Mebeverine+Simethicone","slug":"mebeverine-simethicone","phase":"phase_3","mechanism":"Mebeverine relaxes smooth muscle in the gastrointestinal tract while simethicone reduces gas bloating by breaking down gas bubbles.","indications":["Irritable bowel syndrome with abdominal pain, cramping, and bloating"],"catalyst":""},{"name":"Metofane","genericName":"METHOXYFLURANE","slug":"methoxyflurane","phase":"marketed","mechanism":"Metofane works by binding to the GABA-A receptor and anion channel, enhancing the inhibitory effects of GABA to produce sedation and analgesia.","indications":[],"catalyst":""},{"name":"Mitizax","genericName":"Mitizax","slug":"mitizax","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Niacin ER/Simvastatin Tablets","genericName":"Niacin ER/Simvastatin Tablets","slug":"niacin-er-simvastatin-tablets","phase":"phase_3","mechanism":"Niacin ER/Simvastatin combines extended-release niacin (which increases HDL and lowers triglycerides) with simvastatin (a statin that inhibits HMG-CoA reductase to lower LDL cholesterol).","indications":["Hyperlipidemia and mixed dyslipidemia in patients requiring both statin and niacin therapy","Reduction of cardiovascular risk in patients with coronary heart disease"],"catalyst":""},{"name":"OLE BSA Adalimumab +/- MTX","genericName":"OLE BSA Adalimumab +/- MTX","slug":"ole-bsa-adalimumab-mtx","phase":"phase_3","mechanism":"Adalimumab is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha signaling to reduce inflammation, with optional methotrexate co-administration to enhance efficacy.","indications":["Rheumatoid arthritis (with or without methotrexate)","Ankylosing spondylitis","Psoriatic arthritis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"OLE FD Adalimumab +/- MTX","genericName":"OLE FD Adalimumab +/- MTX","slug":"ole-fd-adalimumab-mtx","phase":"phase_3","mechanism":"Adalimumab is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha signaling to reduce inflammation, with optional methotrexate co-administration to enhance efficacy.","indications":["Rheumatoid arthritis (with or without methotrexate)","Polyarticular juvenile idiopathic arthritis","Ankylosing spondylitis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"Open-labelAdalimumabRescue","genericName":"Open-labelAdalimumabRescue","slug":"open-labeladalimumabrescue","phase":"phase_3","mechanism":"Adalimumab is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha to reduce inflammation and immune-mediated disease activity.","indications":["Rescue therapy in inflammatory bowel disease (Crohn's disease or ulcerative colitis) with inadequate response to standard therapy","Rescue therapy in rheumatoid arthritis with inadequate response to conventional DMARDs"],"catalyst":""},{"name":"Pentothal","genericName":"THIOPENTAL","slug":"thiopental","phase":"marketed","mechanism":"GABA-A receptor alpha-1/beta-2/gamma-2","indications":["Benign intracranial hypertension","Epilepsy","General anesthesia","Narcoanalysis"],"catalyst":""},{"name":"Placebo Eprosartan mesylate","genericName":"Placebo Eprosartan mesylate","slug":"placebo-eprosartan-mesylate","phase":"phase_3","mechanism":"Eprosartan mesylate is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, to lower blood pressure.","indications":["Hypertension"],"catalyst":""},{"name":"Prosom","genericName":"ESTAZOLAM","slug":"estazolam","phase":"marketed","mechanism":"GABA-A receptor alpha-1/beta-2/gamma-2","indications":["Severe Insomnia"],"catalyst":""},{"name":"Racecadotril plus ORS","genericName":"Racecadotril plus ORS","slug":"racecadotril-plus-ors","phase":"phase_3","mechanism":"Racecadotril inhibits enkephalinase to reduce intestinal fluid secretion, while ORS provides oral rehydration therapy to replace lost electrolytes and fluids.","indications":["Acute diarrhea in children","Infectious diarrhea"],"catalyst":""},{"name":"SA-001","genericName":"SA-001","slug":"sa-001","phase":"phase_3","mechanism":"SA-001 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Sevoflurane Inhalational Induction and Maintenance","genericName":"Sevoflurane Inhalational Induction and Maintenance","slug":"sevoflurane-inhalational-induction-and-maintenance","phase":"marketed","mechanism":"Sevoflurane is a volatile anesthetic that depresses the central nervous system by enhancing inhibitory GABA neurotransmission and inhibiting excitatory glutamate signaling.","indications":["Induction and maintenance of general anesthesia in adult and pediatric patients undergoing surgery"],"catalyst":""},{"name":"Testosterone (T) Gel 1.62%","genericName":"Testosterone (T) Gel 1.62%","slug":"testosterone-t-gel-1-62","phase":"phase_3","mechanism":"Testosterone gel delivers exogenous testosterone through transdermal absorption to replace deficient endogenous testosterone in hypogonadal men.","indications":["Testosterone replacement therapy in adult males with hypogonadism"],"catalyst":""},{"name":"adalimumab (D2E7)","genericName":"adalimumab (D2E7)","slug":"adalimumab-d2e7","phase":"phase_3","mechanism":"Adalimumab is a fully human monoclonal antibody that selectively binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"aspirin placebo (ASA Pbo)","genericName":"aspirin placebo (ASA Pbo)","slug":"aspirin-placebo-asa-pbo","phase":"phase_3","mechanism":"Aspirin works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins and thromboxanes.","indications":["Prevention of cardiovascular disease and stroke","Treatment of pain and inflammation"],"catalyst":""},{"name":"cefdinir (Omnicef)","genericName":"cefdinir (Omnicef)","slug":"cefdinir-omnicef","phase":"marketed","mechanism":"Cefdinir is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","indications":["Community-acquired pneumonia","Acute exacerbation of chronic bronchitis","Acute maxillary sinusitis","Pharyngitis/tonsillitis","Uncomplicated skin and skin structure infections"],"catalyst":""},{"name":"felodipine/ramipril","genericName":"felodipine/ramipril","slug":"felodipine-ramipril","phase":"phase_3","mechanism":"Felodipine is a calcium channel blocker that relaxes blood vessels, while ramipril is an angiotensin-converting enzyme (ACE) inhibitor that lowers blood pressure.","indications":["Hypertension","Heart failure"],"catalyst":""},{"name":"hydrocodone / acetaminophen extended release","genericName":"hydrocodone / acetaminophen extended release","slug":"hydrocodone-acetaminophen-extended-release","phase":"phase_3","mechanism":"Hydrocodone is an opioid agonist that binds to opioid receptors in the brain, while acetaminophen is a non-opioid analgesic that works by inhibiting the production of prostaglandins.","indications":["Management of moderate to severe pain"],"catalyst":""},{"name":"metoprolol/HCT","genericName":"metoprolol/HCT","slug":"metoprolol-hct","phase":"phase_3","mechanism":"Metoprolol/HCT is a beta-blocker that works by blocking the effects of the hormone epinephrine, and also has a diuretic effect to reduce blood pressure.","indications":["Hypertension","Atrial fibrillation for stroke prevention"],"catalyst":""},{"name":"paricalcitol capsule","genericName":"paricalcitol capsule","slug":"paricalcitol-capsule","phase":"marketed","mechanism":"Paricalcitol is a selective vitamin D receptor agonist that activates the vitamin D receptor to regulate calcium and phosphorus metabolism and suppress parathyroid hormone secretion.","indications":["Secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis","Secondary hyperparathyroidism in patients with chronic kidney disease stages 3-4 (non-dialysis dependent)"],"catalyst":""},{"name":"placebo adalimumab, placebo MTX","genericName":"placebo adalimumab, placebo MTX","slug":"placebo-adalimumab-placebo-mtx","phase":"phase_3","mechanism":"Adalimumab is a monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors and thereby reducing inflammation.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"raltegravir (RAL)","genericName":"raltegravir (RAL)","slug":"raltegravir-ral","phase":"marketed","mechanism":"Raltegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA.","indications":["HIV-1 infection in treatment-naïve adults and children","HIV-1 infection in treatment-experienced patients"],"catalyst":""},{"name":"sibutramine hydochloride monohydrate","genericName":"sibutramine hydochloride monohydrate","slug":"sibutramine-hydochloride-monohydrate","phase":"marketed","mechanism":"Sibutramine is a norepinephrine-serotonin reuptake inhibitor that increases satiety and reduces appetite by blocking the reuptake of these neurotransmitters in the central nervous system.","indications":["Obesity management (withdrawn from most markets due to cardiovascular safety concerns)"],"catalyst":""},{"name":"trandolapril/verapamil","genericName":"trandolapril/verapamil","slug":"trandolapril-verapamil","phase":"marketed","mechanism":"Trandolapril inhibits angiotensin-converting enzyme (ACE) to reduce blood pressure, while verapamil blocks calcium channels to slow heart rate and further lower blood pressure.","indications":["Hypertension","Angina pectoris"],"catalyst":""}],"recentEvents":[{"date":"2023-02-08","type":"earnings","headline":"Abbott Reports Fourth-Quarter and Full-Year 2022 Results","summary":"Abbott reported fourth-quarter and full-year 2022 results, with revenue of $10.3 billion and adjusted earnings per share of $1.03.","drugName":"","sentiment":"neutral"},{"date":"2022-12-20","type":"deal","headline":"Abbott to Acquire Sight Diagnostics for $450 Million","summary":"Abbott announced the acquisition of Sight Diagnostics, a developer of point-of-care diagnostic tests, for $450 million.","drugName":"","sentiment":"positive"},{"date":"2022-09-02","type":"regulatory","headline":"FDA Approves Abbott's FreeStyle Libre 2 System","summary":"The US FDA approved Abbott's FreeStyle Libre 2 system, a continuous glucose monitoring system for people with diabetes.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxPNTVIb3FYTGdQN3hNajIyMTJYUkQ4RXo3N2JFUnBvNy1hUmhiSjdac3FaY29iQXBfZnB4T1p6OWRxczIwaGJPb29SN2dueDhKbDEydUZXS3NQSEhuZ0lpR1VkUXNRNDhxeWRqczhvUUJVTEgzbFpsbUJWZlludVRtWFd5aVZyeWJLRzVMd0xORUh6Nm5KTmplYktBZzlzN3MyUjFUblVnSHRaYUE1RkhxLXlmcEJOSk9kWTRwWmd6eWgzSHFQaU9obXVQc09TbVRKMmZjYkItVTlrVG9mTkJkeXY4ZXZlT2U3elFxZnJyV2ZDeTA5clUxTWJHUEJOSklCY0lyc3pYMWZidThJY0o1ZlRQc3lXREQ2VkE?oc=5","date":"2026-02-14","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Abbott Laboratories (ABT) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Abbott Laboratories (ABT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxNaVNPOXZ6M3lJTnFaQzBNaEZkMklBdGs4WktPMUhUTnBiMjIzT1pBT2pZWm4wVkF0X2NXUlB0S3BsdlRCRGVfZzQ1ZzVIbGlOWUhldFhKZ21Xdzk4Q0ZpUmNvUzBOQ25OVjJCSkJUcHdmbzlIcW5KYzBqb1N0b1RsMUhudDIwajZvMm1QcHNZdEFYb2JQZzNzdHFzaVg5cW9ORU9TVldqUDN4WVFEbzZWNFItVFBoLTdobnVxVkNyT0hTMUZULXFLVU03TlFtbGdlOTFsbG9tc2ZHUTZQ?oc=5","date":"2026-02-04","type":"regulatory","source":"Reuters","summary":"US FDA says injuries from Abbott's recalled glucose sensors reach 860 - Reuters","headline":"US FDA says injuries from Abbott's recalled glucose sensors reach 860","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxONXRCMVRYSFZkdDgxZUFqQWhkRkdhUU1ZdTRRUWxtLW1UYV9YMURhSzR0VHhIeVFXM3J5aWk5S2pQejRfQUtVcDdOWEZ1M2hVZTUyT282SXpKOGJCWURxUFdyd1ZLU3lSOW1BU0VVWVV2LXM2blBpc1c0Y3ZVdEVGbHFhVHp6ZlIza2lGS3NEYkdab0tMM3RpZXhRU0dKZ2RPal9FUGNLZTZuRzA?oc=5","date":"2026-01-28","type":"pipeline","source":"TIKR.com","summary":"Here’s Why Abbott Stock Could Deliver 10% Upside in 2026 After a 15% Decline Last Year - TIKR.com","headline":"Here’s Why Abbott Stock Could Deliver 10% Upside in 2026 After a 15% Decline Last Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOX1pBN09FRHAzM0xpV3NkQWliVHp1TEJ3cnBnMU0teUoza21tTUVNMlBPeDZnTV9DUzNZTGdLYmZCRUJwc2kwX0pFbFQ0MEUwTGZteGZKdVZFQXcxcnFiWVFlVlpsWGV3cnRUVHpZMm5vRmpYSjN5VWFTOEFVLTJyMm83LWpkUGdxLW1RbG1CRTJ2SVRCLUhN?oc=5","date":"2026-01-22","type":"earnings","source":"Investor's Business Daily","summary":"Abbott Tumbles On Disappointing Fourth Quarter As Exact Closing Looms - Investor's Business Daily","headline":"Abbott Tumbles On Disappointing Fourth Quarter As Exact Closing Looms - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNSWhzbUMwZERyemVlanhPeUtWVHVaT25RdmhqN3BsOGtzTFlhZnJqWXhENWYtOHFpY21QekNUNGR0M3E5MzhDTk5GRmJDbW1UTzdSWjcyeGUwU0J0Z19iS3VmOGZJTUVWRjlrRUZrRlhQWWlBYm5tZlRrWmp4aUltMmNVWU9LREhERXJBRUktVjgzQQ?oc=5","date":"2026-01-22","type":"earnings","source":"Seeking Alpha","summary":"Abbott posts Q4 topline miss as Nutrition unit contracts (ABT) - Seeking Alpha","headline":"Abbott posts Q4 topline miss as Nutrition unit contracts (ABT)","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNblRnYm9RQ1I0cElxZDdaNXlFUkNKLUNQc3N1VW43MC02OTZqeTVLTnI4eXp3d0lGaGlDLTh4b2dMcnRvRXVieXVUNzI5dnZhNVZXR3dzZ2tpWmJBdEhkRmJBdHozWWVfR094VEVQZlRpZTVxaXJfS3A0ZWFLcW9SY3lOcF9FZG5zYlNXdk4zdXpRU2JPTzZGRWs0T0sxM0FFWUZ2TkMzQkstenduTTZqOWljVHh2SXdq?oc=5","date":"2026-01-22","type":"earnings","source":"TradingView","summary":"Abbott's Q4 Earnings Meet Estimates, Revenues Miss, Stock Falls - TradingView","headline":"Abbott's Q4 Earnings Meet Estimates, Revenues Miss, Stock Falls","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNc0ZQV2ZYMklYcWdaY2hTUThWejR1U181U3YwUEJiM3Y0cjJqUExLZmlySlVrTHY1QjZ0SHpjUFVNRnNRa3JuSkptRlJ0UUdkVnJvV2JHSGlUbVNHQ2lJYWFZcFhINEhXUFZpQkIzOU5HQ2YwTnVWZUNsbmhsNV9paFhjeWxaWHV6eDRQSDdXWHB4N01INi16MDF3UXc4dTFCWkt2Nll5WHZna0ptaWN6YTRlTTFROE1hYlI0?oc=5","date":"2026-01-18","type":"trial","source":"Finviz","summary":"Abbott Laboratories (ABT) Positioned to Benefit as Healthcare Sector Enters Recovery Phase - Finviz","headline":"Abbott Laboratories (ABT) Positioned to Benefit as Healthcare Sector Enters Recovery Phase","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQSjNkcTZrdW0tZzZLWFdYaG9vRGhJVHZfaGJCSjFpY2p4RDZoZmlDX3pjN3M4SmNVQnMyWVB5dnNwT0FzY2ZJdjRjWVRRSld4ZjJkRGhNY1JfdVlRVVh3T3FtbmRSMGRkMFZKS2tuNzdYemllekJ3LWtNOXMtZ3F5MGNkVTAxRUhSWHY3d2tBWkxROG14OElIZndENWNydG4tZXhUclluc3FlNmo1eURqeWt3OEVRWEotbkNpYmdFVkdkUzM0TjA3T0dkYlR6dWV6ZkZHd3hJMUc3SGRpVHJiQ2t6ZWdjNUd6?oc=5","date":"2026-01-01","type":"pipeline","source":"FinancialContent","summary":"The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature - FinancialContent","headline":"The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQaWlpTUZJZ3VRU2M0WlBRcUpHMURZX2ZFZDBEMFJiaFBPVlExdFpaaUNsaW8zT3pydXBjNmhlNEF4VkNQTkZlOU9FS0JhS0xBeFNBVlJTZ2haQll1OFI2ZDdCYlllYnIxNDhkQkRFZmQxY2gwUGVzcmkxTjlXVmxRVkc5LTU0em5ScmNaTw?oc=5","date":"2025-10-15","type":"earnings","source":"Seeking Alpha","summary":"Abbott Laboratories stock down on Q3 topline miss (ABT:NYSE) - Seeking Alpha","headline":"Abbott Laboratories stock down on Q3 topline miss (ABT:NYSE)","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxNV3pvRFVRc0lEOTdiNTRqWW5td0hDTXZzbnFoY2tJWkpwc09SS3l0Ny1pN2U5eVFOOC00RURrQUlTN05VTkdtSDI0dHN4eExlZks4Ukp5Qzc2eWdZTUZ4RmdOSHhCMXJFS2dQWWlaVVVRQXowTHI2bHd6Wlg5ZU9LeHJ6b29UU0UzTE5URjdsaEZXYXpNUkpnSEJ3V1l2X2x3VlZROVZVamNZWUM3ckRvM3Fvb1QxMmhJUVVQWHR0cXhReUs4d1NUT0NMVk9fdTJVTUxfTTZwZlMyRmdERmZNVUx3?oc=5","date":"2025-09-30","type":"pipeline","source":"proactiveinvestors.com","summary":"Healthcare equipment stocks seen outperforming, ‘safer’ than Big Pharma: analysts - proactiveinvestors.com","headline":"Healthcare equipment stocks seen outperforming, ‘safer’ than Big Pharma: analysts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNdExZUnlMejJSOW9Wc3N6NXpDY3hFczVfMW1aTGZMbF9jcmhITVNWd3dGNl8xTHl5a3c4MVg3Q3V2NjFHY19CbnQtNjZZb3pCT2tIMFg2ZXhuQ0xHeDJSTFhVVHBoMWowamM1cmZUYlhwcHJaYzZrS0l6eG9DOEtiZExYWFk3Uy11XzE0VkVpSGI?oc=5","date":"2025-09-24","type":"pipeline","source":"Yahoo Finance","summary":"Building Consistent Income in a Dividend Stock Portfolio with Abbott Laboratories (ABT) - Yahoo Finance","headline":"Building Consistent Income in a Dividend Stock Portfolio with Abbott Laboratories (ABT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNRk5DelBHOG1EOE9UVGpxMDRhOGtucEY3eHdJOGkwc1RsaEE4RHJ1N1RlT2FWN205cDVHM3JmeTIxaXNUdXZwZzBkcEFINjIwZDNWeXJFTnFremQ3TmVsb0dSbnA0Xy1zY1J2LURqazdrMjdmV203M3ZtSnc5TjVrQ3pCZllHWFJpNklLNlJvQzRNZmVsWmRv?oc=5","date":"2025-07-17","type":"pipeline","source":"Investor's Business Daily","summary":"Abbott Laboratories Sheds 8% On A Rare Guidance Miss - Investor's Business Daily","headline":"Abbott Laboratories Sheds 8% On A Rare Guidance Miss - Investor's Business Daily","sentiment":"neutral"}],"patents":[{"drugName":"Humira","drugSlug":"adalimumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2026-06-01","territory":"US","annualRevenue":10300000000}],"drugCount":53,"phaseCounts":{"marketed":18,"phase_3":29,"phase_1":5,"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Johnson & Johnson","Becton Dickinson and Company","Medtronic plc"],"therapeuticFocus":["Cardiovascular","Neurology","Oncology"],"financials":{"source":"sec_edgar","revenue":44328000000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":44328000000,"period":"2025-12-31"},{"value":41950000000,"period":"2024-12-31"},{"value":41950000000,"period":"2024-12-31"},{"value":40109000000,"period":"2023-12-31"},{"value":40109000000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":2942000000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":6524000000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":86713000000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":103.32,"previousClose":101.83,"fiftyTwoWeekHigh":139.06,"fiftyTwoWeekLow":100.88,"fiftyTwoWeekRange":"100.88 - 139.06","fiftyDayAverage":109.36,"twoHundredDayAverage":124.14,"beta":0.78,"enterpriseValue":182786244608,"forwardPE":16.9,"priceToBook":3.44,"priceToSales":4.05,"enterpriseToRevenue":4.12,"enterpriseToEbitda":15.19,"pegRatio":1.49,"ebitda":12033000448,"ebitdaMargin":27.1,"freeCashflow":6288999936,"operatingCashflow":9566000128,"totalDebt":14136000512,"debtToEquity":26.8,"currentRatio":1.58,"returnOnAssets":6.6,"returnOnEquity":13,"analystRating":"1.7 - Buy","recommendationKey":"buy","numberOfAnalysts":25,"targetMeanPrice":132.12,"targetHighPrice":158,"targetLowPrice":113,"dividendRate":2.52,"payoutRatio":0.63,"fiveYearAvgDividendYield":1.77,"exDividendDate":1776211200,"insiderHeldPercent":0.5,"institutionHeldPercent":82,"sharesOutstanding":1737674869,"floatShares":1727152529,"sharesShort":19950568,"shortRatio":2.35,"shortPercentOfFloat":1.1,"epsTrailing":3.72,"epsForward":6.1,"revenuePerShare":25.46,"bookValue":30.02,"officers":[{"age":51,"name":"Mr. Robert B. Ford","title":"Chairman, President & CEO"},{"age":52,"name":"Mr. Philip P. Boudreau","title":"CFO & Executive VP of Finance"},{"age":46,"name":"Mr. Daniel Gesua Sive Salvadori","title":"Executive VP and Group President of Established Pharmaceuticals & Nutritional Products"},{"age":55,"name":"Mr. Christopher J. Scoggins","title":"Executive Vice President of Diabetes Care"},{"age":55,"name":"Ms. Lisa D. Earnhardt","title":"Executive VP & Group President of Medical Devices"},{"age":51,"name":"Ms. Sabina  Ewing","title":"Senior VP of Business & Technology Services and Chief Information Officer"},{"age":null,"name":"Mr. Michael  Comilla","title":"Vice President of Investor Relations."},{"age":null,"name":"Erica L. Battaglia","title":"VP and Chief Ethics & Compliance Officer"}],"industry":"Medical Devices","irWebsite":"http://www.abbottinvestor.com/phoenix.zhtml?c=94004&p=irol-irhome","website":"https://www.abbott.com","phone":"224 667 6100"}}